A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers

• Principais autores: Jin Wang (Autor), Lu Qi (Autor), Long Liu (Autor), Zejuan Wang (Autor), Gang Chen (Autor), Yu Wang (Autor), Xiaona Liu (Autor), Ying Liu (Autor), Huijuan Liu (Autor), Yuanxu Tong (Autor), Chen Liu (Autor), Chunpu Lei (Autor), Xinghe Wang (Autor)
• Formato: Livro
• Publicado em: Frontiers Media S.A., 2019-08-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Objective: This study compared the pharmacokinetics (PK), safety, and immunogenicity of the biosimilar TAB008 monoclonal antibody to bevacizumab (Avastin®) in normal healthy Chinese male volunteers.Methods: In this randomized, double-blind, parallel controlled study, a total of 100 healthy Chinese m...